MDS-Bio1

Trial overview

Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS) and secondary disorders of haematopoiesis

Inclusion criteria

i) Patients with an abnormal blood count requiring investigation by blood and bone marrow sample.

ii) Patients known to have a blood disorder who are having a bone marrow sample taken as part of the assessment of that disorder.

Control subjects

Patients having elective orthopaedic surgery who have a normal blood count.

 

Exclusion criteria

i) Age < 18.

Controls

i) Age <18.

ii) On treatment likely to impair bone marrow function

iii) History of having had treatment likely to have impaired bone marrow function

Contact details

Principal Investigator

Prof. David Bowen

Tel 0113 2068481

Email david.bowen@leedsth.nhs.uk

Research Nurse

Alex Stichler

Tel 0113 2068577

Email alex.stichler@leedsth.nhs.uk



Other trials currently active for Myelodysplastic Syndromes

AML Len 5

A pilot safety / tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for
Acute Myeloid Leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5

Amgen 198 Romiplostim

A randomised, double blind, placebo controlled study evaluating the efficacy and safety of romiplostim treatment of thrombocytopenia in subjects with international prognostic scoring system (IPSS) low or intermediate-1 risk Myelodysplastic Syndrome (MDS) as measured by the number of clinically significant bleeding events.

AML 17

The AML 17 trial has two distinct parts:

i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).

ii.For adults with acute promyelocytic leukaemia (APL).

 


Tags

mds bone marrow haematopoiesis secondary disorders